



Wisconsin State
Laboratory of Hygiene

UNIVERSITY OF WISCONSIN-MADISON



2014 Update: STEC Diagnosis and Surveillance in Wisconsin

Mike Rauch
Tim Monson
WI State Laboratory of Hygiene
Communicable Disease Division

WCLN Teleconference
March 19, 2014





Objectives

- Describe the history of Shiga toxin-producing *E. coli* (STEC) in Wisconsin
- Discuss available diagnostic tests for the detection of Shiga toxins in clinical specimens
- Gain an appreciation for the significance of STEC disease in WI and nationally
- Understand testing that is performed at WSLH and CDC on STEC specimens submitted by clinical health systems




Objectives

- Become aware of ongoing developments in STEC diagnostic testing (Culture-independent diagnostic testing- CIDT) and their potential effects on both clinical and public health laboratories and officials
- Understand the importance of the partnership between clinical, public and environmental health for effective disease surveillance and prevention



Shiga toxin-producing *Escherchia coli* (STEC)





What is STEC?

- Shiga toxin-producing *E. coli* (STEC)—STEC may also be referred to as Verocytotoxin-producing *E. coli* (VTEC) or enterohemorrhagic *E. coli* (EHEC). This pathotype is the one most commonly heard about in the news in association with foodborne outbreaks.



Pathotypes of *E. coli*

- enterotoxigenic *E. coli* (ETEC)
- enteropathogenic *E. coli* (EPEC)
- enteroinvasive *E. coli* (EIEC)
- enteroaggregative *E. coli* (EAEC)
- diffusely adherent *E. coli* (DAEC)
- enterhemorrhagic *E. coli* (EHEC)



Serogroups

Table 1. Laboratory-confirmed STEC infections reported to CDC, with the 20 most frequently reported serogroups listed individually, United States, 2011

Rank	Serogroup	Number Reported	Percent
1	O157	2366	41.1
2	O26	611	10.6
3	O103	548	9.5
4	O111	322	5.6
5	O121	176	3.1
6	O45	135	2.3
7	O145	74	1.3
8	O118	47	0.8
9	O69	22	0.4
10	O76	14	0.2
11	O91	14	0.2
12	O5	9	0.2
13	O153	8	0.1
14	O104	7	0.1
15	O113	6	0.1
16	O165	6	0.1
17	O174	6	0.1
18	O71	6	0.1
19	O146	5	0.1
20	O80	5	0.1
	Sub Total	4387	76.1
	All other non-O157 STEC	89	1.5
	Unknown*	1200	20.8
	Rough	79	1.4
	Undetermined	8	0.1
	Sub Total	1376	23.9
		5763	100



Virulence Factors

- Two distinct Shigatoxins (Stx1 and Stx2)
- *Shigella dysenteriae* 1
- Range in virulence
- Additional virulence factors.
 - *eae* gene for intimin
 - *ehxA* gene for plasmid encoded hemolysin



Virulence Factors

Table 3. Presence of Virulence Genes in Shiga Toxin–Producing *Escherichia coli* Isolates From Patients With Postdiarrheal Hemolytic Uremic Syndrome by Serogroup, 2000-2010

Serogroup	Shiga Toxin			<i>eae</i> ^a	<i>ehxA</i> ^a
	<i>stx1</i> Alone	<i>stx2</i> Alone	<i>stx1</i> and <i>stx2</i>		
O157 (n = 103) ^b	0/103	78/103 (75.7)	25/103 (24.3)		
O111 (n = 4) ^c	0/4	0/4	4/4 (100)	4/4 (100)	4/4 (100)
O121 (n = 2) ^c	0/2	2/2 (100)	0/2	2/2 (100)	2/2 (100)
O145 (n = 5)	0/5	5/5 (100)	0/5	5/5 (100)	5/5 (100)
O26 (n = 2) ^d	1/2 (50.0)	0/2	1/2 (50.0)	2/2 (100)	1/2 (50.0)
O103 (n = 1)	1/1 (100)	0/1	0/1	1/1 (100)	1/1 (100)
O130 (n = 1)	0/1	1/1 (100)	0/1	0/1	1/1 (100)
Unknown (n = 1) ^c	0/1	0/1	1/1 (100)		
Total	2/119 (1.7)	86/119 (72.3)	31/119 (26.1)	14/15 (93.3)	14/15 (93.3)

^a *eae* encodes intimin, and *ehxA* encodes enterohemolysin; *eae* and *ehxA* data were not available for STEC O157 (test not generally performed because genes almost invariably present) or for isolates of unknown serogroup.

^b Shiga toxin data collected for 103 of 135 STEC O157 isolates (76.3%) from 2007 through 2010.

^c Virulence factor information is not available for 1 isolate from each of the following serogroups: O111, O121, and unknown.

^d Excluded 1 *Stx1*-only STEC O26 isolate from a patient whose stool sample also yielded a *stx2*-only STEC O157 isolate.

From: Infections in Pediatric Postdiarrheal Hemolytic Uremic Syndrome: Factors Associated With Identifying Shiga Toxin–Producing *Escherichia coli*

Arch Pediatr Adolesc Med. 2012;166(10):902-909. doi:10.1001/archpediatrics.2012.471



STEC- Background Information

- CDC estimates 19% of O157 STEC and 9% of non-O157 STEC are outbreak related (majority of cases sporadic)
- STEC are low-infectious dose organisms (10-100 cells)
- STEC virulence dependent upon which virulence factors are present in a given strain (Stx1/Stx2, eae, Ehly); evidence suggests Stx and eae are most significant predictors of serious illness



Common Symptoms of STEC Disease

- Diarrhea (sometimes bloody)
- Severe stomach cramps
- Vomiting
- Fever less than 101°F






STEC Complications

- Hemolytic Uremic Syndrome (HUS)
 - Occur in about 5–10% of cases
 - Usually STEC O157
 - Renal failure
 - Hemolytic anemia
 - Thrombocytopenia
 - Most recover within a few weeks, but some suffer permanent damage or die




Sequence of events in STEC infection





Where does STEC come from?

It wasn't me,
the dog did it!






Incidence

- 265,000 Illnesses annually in U.S.
- 3,600 plus hospitalizations
- 30 deaths
- 96,534 STEC O157
- 168,698 non-O157



Incidence

Figure 1. Incidence rate of laboratory-confirmed human STEC infection reported to CDC per 100,000 population, by serogroup and year, United States, 1996–2011 (n=50,158)




Centers for Disease Control and Prevention (CDC). National Shiga toxin-producing Escherichia coli (STEC) Surveillance Annual Report, 2011. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2013.



Incidence

Figure 3b. Incidence rate of laboratory-confirmed non-O157 STEC infection reported to CDC, by age group and sex, United States, 2011 (n=2,014)




Centers for Disease Control and Prevention (CDC). National Shiga toxin-producing Escherichia coli (STEC) Surveillance Annual Report, 2011. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2013.



STEC

Figure 2a. Incidence rate of laboratory-confirmed STEC infection reported to CDC, by state, United States, 2011 (n=5,763)*




Centers for Disease Control and Prevention (CDC). National Shiga toxin-producing Escherichia coli (STEC) Surveillance Annual Report, 2011. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2013.



Non-O157 STEC

Figure 2c. Incidence rate of laboratory-confirmed non-O157 STEC infection reported to CDC, by state, United States, 2011 (n=2,118)*



Centers for Disease Control and Prevention (CDC). National Shiga toxin-producing Escherichia coli (STEC) Surveillance Annual Report, 2011. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2013.




Figure 2d. Incidence rate of laboratory-confirmed non-O157 STEC infection, top 6 non-O157 STEC serogroups, reported to CDC by state, United States, 2011 (n=1,866)

Legend Rate per 100,000 population

0.005–0.44 0.45–0.61 0.62–1.04 1.05–1.85 1.86–2.40 No infections were diagnosed or the state did not report to CDC.

STEC O26 (n=611)



- 37 states reported 611 laboratory-confirmed STEC O26 infections, corresponding to an incidence rate (cases per 100,000 population) of 0.20

STEC O103 (n=548)



- 36 states reported 548 laboratory-confirmed STEC O103 infections, corresponding to an incidence rate of 0.18

STEC O111 (n=322)



- 36 states reported 322 laboratory-confirmed STEC O111 infections, corresponding to an incidence rate of 0.10

STEC O121 (n=176)



- 31 states reported 176 laboratory-confirmed STEC O121 infections, corresponding to an incidence rate of 0.06

STEC O45 (n=135)



- 21 states reported 135 laboratory-confirmed STEC O45 infections, corresponding to an incidence rate of 0.04

STEC O145 (n=74)



- 25 states reported 74 laboratory-confirmed STEC O145 infections, corresponding to an incidence rate of 0.02

The "Big Six"

Centers for Disease Control and Prevention (CDC). National Shiga toxin-producing Escherichia coli (STEC) Surveillance Annual Report, 2011. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2013.



What About Wisconsin?





2010 – 2013 STEC Confirmed Cases (n=1013)

O157 vs. NonO157

- O157 – 492
- NonO157 – 521

Big 7 vs. NonO157


- Big 7 – 935
- NonBig7 – 78

O group	Number
O157	492
O111	127
O103	140
O26	73
O45	57
O145	17
O121	29
Other	78 (none identified >4 times)



O157 vs. non-O157 STEC


* as of 3/11/2014






O157 vs. non-O157 STEC

WI 2010 - 2013




2011 National LEDS






Agencies & STEC Isolated






2010-13 O157 STEC






2010-13 non-O157 STEC





2010-13 Combined STEC





Wisconsin Case Definition:

- **Confirmed:** A case that meets the laboratory criteria for confirmation. When available, O and H antigen serotype characterization should be reported
- **Probable:** A case with isolation of *E. coli* O157 from a clinical specimen, without confirmation of H antigen or Shiga toxin production, OR a clinically compatible case that is epidemiologically linked to a confirmed or probable case, OR identification of an elevated antibody titer to a known Shiga toxin-producing *E. coli* serotype from a clinically compatible case
- **Suspected:** Identification of Shiga toxin in a specimen from a clinically compatible case without the isolation of the Shiga toxin-producing *E. coli*




Laboratory Criteria for Confirmation:

- Isolation of Shiga toxin-producing Escherichia coli from a clinical specimen.
- E. coli O157:H7 isolates may be assumed to be Shiga toxin-producing.
- For all other E. coli isolates, Shiga toxin production or the presence of Shiga toxin genes must be confirmed to be considered STEC. Examples of assays used to detect Shiga toxin production include Shiga toxin EIA or PCR.



<http://www.cdc.gov/mmwr/PDF/rr/rr5812.pdf>



**Recommendations for Diagnosis of Shiga Toxin-
Producing *Escherichia coli* Infections
by Clinical Laboratories**



Guidelines for the Clinical Laboratory:

- All stools submitted for testing from patients with acute, community-acquired diarrhea should be cultured for **O157** STEC on selective and differential media
- Stools from patients with acute, community-acquired diarrhea should be simultaneously tested for **non-O157** STEC with a test that detects either Shiga toxins or the genes that encode for these toxins



Guidelines for the Clinical Laboratory:

- All O157 STEC isolates should be forwarded as soon as possible to a state or local public health laboratory (PHL) for confirmation and molecular characterization (PFGE, MLVA, virulence genes)
- Detection of STEC or Shiga toxin should be promptly reported to the physician, PHL and proper public health authorities




Guidelines for the Clinical Laboratory:

- Any specimens or enrichment broths in which Shiga toxin or STEC has been detected but from which no **O157** STEC isolates are recovered, should be forwarded as soon as possible to a state or local public health laboratory for isolation of the STEC



Clinical Laboratory Recommendations





Justification for STEC Testing

- STEC may be as or more prevalent than other enteric bacterial pathogens routinely tested for:
 - STEC may be found in 0-4% of stools
 - *Salmonella* may be found in 1.9-4.8%
 - *Shigella* may be found in 0.2-3.1%
 - *Campylobacter* may be found in 0.9-9.3%

FoodNet Data, CDC




Early HUS Identification and Treatment is Critical

- 15% of culture + *E. coli* O157:H7 patients < 10 yrs of age will develop HUS
- Strong evidence suggesting that STEC isolates that produce Stx2, and in particular Stx2 only, have a higher likelihood to lead to HUS development
- Evidence supporting improved outcomes in individuals that receive prompt intervention (parenteral fluid admin. may prevent renal damage)



Prevention of Illness is Hard to Measure; Hard to Sell


- Even though non-O157 STEC are low prevalence, single case of HUS may cost the healthcare system over \$6.1 million





Annual Cases by Severity

Figure 1
Distribution of annual STEC O157 cases by severity




Source: USDA, ERS estimate based on FoodNet data, reported in Frenzen et al. (2005).



Costs by Severity

Figure 2
Distribution of annual economic costs of STEC O157 by severity



Source: USDA, ERS estimate reported in Frenzen et al. (2005).



Economic Costs

Table 1
**Annual economic cost of illness due to Shiga toxin-producing
E. coli (STEC) O157**

Severity category	Estimated annual STEC O157 cases ¹	Estimated annual economic cost ²	Estimated average cost per case ²
	<i>Number</i>	<i>Million dollars</i>	<i>Dollars</i>
Nonfatal cases			
1. Not hospitalized, did not see a physician	57,656	1.5	26
2. Not hospitalized, saw a physician	13,656	6.0	441
3. Hospitalized, did not have HUS	1,797	10.1	5,599
4. Hospitalized, had HUS but not ESRD	300	9.3	30,998
5. Hospitalized, had HUS and ESRD	10	51.7	5,173,594
Fatal cases			
6. Did not have HUS	23	92.0	3,998,265
7. Had HUS	38	234.7	6,175,500
Total	73,480	405.2	5,515

Notes: HUS = hemolytic uremic syndrome. ESRD = end-stage renal disease.

¹Derived from the CDC estimate of the annual number of STEC O157 cases, hospitalizations, and deaths in 1997. See Frenzen et al. (2005).

²2003 dollars. The average cost per case was calculated from unrounded totals.

Source: USDA, ERS using data from Frenzen et al. (2005).



Testing at WSLH






WSLH Culture Results


CT-SMAC Plate

(sorbitol fermentation positive; sorbitol negative example inset)




Washed SBA Plate

(non-hemolytic; example of an expected STEC Ehly + result inset)





***E. Coli* O157:H7 on SMAC Plate**






WSLH PCR Results

stx1 and *stx2* detection- fluorescent probes

LightCycler Analysis Settings Report

User: many LightCycler ID#: 1211
Run Version: 5.32 Analysis Version: 3.6.20

File: C:\LightCycler\Users\many\Data\STEC 111303 TMA8T Program: PCR Run By: many
Run Date: Nov 13, 2010 15:56 Print Date: September 17, 2011




stx1 and *stx2* differentiation by melting temperature

LightCycler Manual Tm Estimation Report

User: many LightCycler ID#: 1211
Run Version: 5.32 Analysis Version: 3.6.20

File: C:\LightCycler\Users\many\Data\STEC 111303 TMA8T Program: Melting Curve Run By: many
Run Date: Nov 13, 2010 15:56 Print Date: September 17, 2011






WSLH Serogrouping

- O157 and big six non-O157 by slide agglutination






WSLH PFGE Subtyping






WSLH PFGE Subtyping





PFGE

The PFGE Process



National Center for Emerging and Zoonotic Infectious Diseases
Office of the Director






MLVA

MLVA Process (Multiple Locus Variable-Number Tandem Repeat Analysis)

Bacterial Culture



1 Scientists take bacterial cells from an agar plate and boil the cells to release DNA.


2 Scientists have to detect the DNA region needed for this type of fingerprinting, called the variable-number tandem repeat arrays (VNTR). To do this, they use polymerase chain reaction (PCR), which combines the DNA with chemicals to amplify the VNTR.




4 Scientists load the PCR products into a sample analysis plate and mix them with chemicals that help them determine the size of the product.



3 After PCR, scientists must determine the size of the PCR products. The different sizes will tell scientists how related the bacterial strains are to each other.



5 Using capillary electrophoresis, the fragment analysis solution is run through a gel matrix in an electric field to determine the sizes of the DNA fragments.



6 The data output of the MLVA process is called an electropherogram. It shows the DNA standards of known size in red, and the sizes of the PCR products in blue, green, and black. The PCR products sizes are converted into allele types using special software, which lets scientists determine how closely they are related.





PulseNet

- PulseNet USA is made up of 87 federal, regional, state, and local laboratories. There is at least one PulseNet laboratory in every state.
- In 2012, participating laboratories reported over 60,000 isolates to PulseNet. Over 4,000 of these isolates were from food, animal, or environmental sources.
- Each year in the United States, 1,200 clusters of disease are identified by state and local health agencies and 10—15 multistate or national outbreaks are identified.



PulseNet

- PulseNet tracks subtypes of:
 - *E. coli* O157 and other Shiga toxin-producing- *E. coli*
 - *Campylobacter jejuni*
 - *Clostridium botulinum**
 - *Listeria monocytogenes*
 - *Salmonella*
 - *Shigella*
 - *Vibrio cholerae*
 - *Vibrio parahaemolyticus*




Available Testing Options

- ELISA's
- RCA's
- CIDT's
- Future?





ELISA



 **Meridian**
Bioscience, Inc.
Inspired Science. Trusted Solutions.™



©2012 Thermo Fisher Scientific Inc. All rights reserved.


ProSpect

- Common procedure and reagents for all tests
- Flexible specimen transport options
- Results within 100 minutes
- Visual or spectrophotometric reading

Thermo
SCIENTIFIC



Rapid Cartridge Assays




DEFINITIVE ANSWERS, CONFIDENT RESULTS

- Fully comply with CDC guidelines
- Detects ALL Shiga toxin-producing *E. coli*, not just *E. coli* O157:H7
- Rapid identification to avoid contraindicated antibiotic therapy



RESULTS





Rapid Cartridge Assays

AlereTM

Distributed by:

AlereTM

Developed and
Manufactured by:

TECHLAB

Detect **STEC** toxins direct from fecal samples with the new **SHIGA TOXIN QUIK CHEK** test.




Positive STX1
Positive STX2



Positive STX1
Negative STX2



Negative STX1
Positive STX2



Negative STX1
Negative STX2

Direct Fecal Testing Results



Culture-Independent Diagnostic Tests (CIDT)

- They have arrived!
- Two multiplex GI panel tests are now available for use (Luminex xTAG GPP and Prodesse ProGastro SSCS)
- Many others at various stages of development
- Will change the landscape of GI pathogen diagnostics and surveillance



Luminex xTAG GPP-ASR/RUO Kits

NEW xTAG[®] Gastrointestinal Pathogen Panel (GPP) for In Vitro diagnostic use

Multiplexed molecular testing for a reliable, actionable result in *under 5 hours*

- xTAG GPP is the only test that simultaneously detects and identifies the bacterial, viral, and parasitic pathogens responsible for over 95% of cases of infectious diarrhea¹
- xTAG GPP provides:
 - More answers per sample than any other method
 - A reliable answer, in time to affect patient care
 - Better use of time and human resources

xTAG GPP – More results per test than any other method, in time to affect patient care

Method	Tests for	Turn-around time	Diagnostic yield
Stool culture	Single bacterial pathogen per test	2–3 days	Up to 6% ²
Ova and parasite (O&P) exam	Parasitic pathogens	Several days – sample must be collected over 3 days	Up to 3% ^{3,4}
Rapid tests	Single pathogen per test	20–30 min	Varies
Real-time PCR	1–3 pathogens per test	Under 5 hours	Varies; depends on the pathogen target, individual performance and number of assays
ELISA	Single antigen/antibody per test	6–24 hours	Varies
xTAG GPP	Up to 15 bacterial, viral, and parasitic pathogens in a single test	Under 5 hours*	30%

xTAG GPP – the only available gastrointestinal infection diagnostic that detects bacterial, viral and parasitic pathogens in a single test

*including extraction steps




Prodesse ProGastro SSCS GI Panel

HOLOGIC | GEN-THIOM

Prodesse[®]
ProGastro[™] SSCS

Instructions for Use

For the detection and differentiation of Salmonella, Shigella, Campylobacter (C. jejuni and C. coli only, undifferentiated) nucleic acids, and Shiga Toxin Producing E. coli (STEC) Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes.



REF
303278

503156 V B 14 February 2013

1



bioMérieux (BioFire) GI Panel

FilmArray Gastrointestinal Panel

1 Test. 23 Targets. All in about an hour.



Bacteria

Aeromonas
Campylobacter
Clostridium difficile (Toxin A/B)
Plesiomonas shigelloides
Salmonella
Yersinia enterocolitica
Vibrio
Vibrio cholerae
Diarrheagenic *E. coli*/Shigella
Enteroaggregative *E. coli* (EAEC)
Enteropathogenic *E. coli* (EPEC)
Enterotoxigenic *E. coli* (ETEC) *lt/st*
Shiga-like toxin-producing *E. coli* (STEC) *stx1/stx2*
E. coli O157
Shigella/Enteroinvasive *E. coli* (EIEC)



Protozoa

Cryptosporidium
Cyclospora cayetanensis
Entamoeba histolytica
Giardia lamblia



Viruses

Adenovirus F 40/41
Astrovirus
Norovirus GI/GII
Rotavirus A
Sapovirus





The Future of “DNA Fingerprinting”

- Whole genomic sequencing
 - Requires pure cultures of bacteria
 - Use whole genome sequencing which by itself is a very powerful DNA fingerprinting method to help identifying and investigating outbreaks
 - Identify genetic targets for surveillance
 - Build reference database for metagenomics



The Future of "DNA Fingerprinting"

Key Factors	Next Generation Sequencing (NGS)	Current "Gold Standard" (PFGE)
Time to get data	1-2 days	Days
Time to analyze data	Hours to days	Hour or less
Cost per bacteria isolate (for reagents only)	~\$150-300 (depends on platform)	~\$10-15
Ability to differentiate and cluster isolates	To be determined but likely very good	Well-established for bacteria tracked by PulseNet, few exceptions
Potential for automation	Yes	No
Intended objective	Genetic serotyping, virulence, antimicrobial resistance profiling, and subtyping possibly based on SNPs or other variant regions	Only subtyping



The Future of “DNA Fingerprinting”

- Metagenomics
 - No pure culture of bacteria required
 - Sequence select genetic targets or all bacteria in a patient sample (stool, blood, etc.)
 - Identify bacteria making a patient sick and subtype at the same time



Studies



2011-2012 FoodCORE Study

- **FoodCORE: Food**borne diseases **C**enters for **O**utbreak **R**esponse **E**nhancement
- Public Health systems (Lab, Epi and Environ) granted funding to improve and model enhanced foodborne disease diagnostics, surveillance and prevention of further disease
- WI was one of 7 systems awarded funding in 2009; began laboratory activities in 2010
- Addressing STEC disease is one of the major foci for WI FoodCORE activities



2011-2012 FoodCORE Study

- Three clinical sites not performing routine Shiga toxin (Stx) screening of stool specimens were enlisted to participate
 - **Site 1** inoculated GN enrichment broth and sent to WSLH for microplate EIA Stx screening
 - **Site 2** performed microplate EIA screening for Stx in-house
 - **Site 3** performed Stx screening using a lateral flow rapid cartridge assay



2011-2012 FoodCORE Study

- Total of 8180 stools were screened for Stx from the three clinical system sites (Mar 1, 2011-Dec 31, 2012)
- There were 83 primary STEC isolates detected, of which 46 were O157 and 37 non-O157 STEC
- STEC recovered from the three clinical system sites represented 15% of the O157 STEC and 12% of the non-O157 STEC reported in WI over the study period (14% of total STEC **WSLH rec'd**)



STEC isolated during study:

E. coli O5:NM

E. coli O121:H undetermined

E. coli O145:NM

E. coli O26:NM and H undetermined

E. coli O146:H21

E. coli O103:H undetermined

E. coli O157:H7 and O157:NM

E. coli O45:H2 and H undetermined

E. coli O111:NM

E. coli O91:H14

E. coli O undetermined: H undetermined*

*CDC unable to serotype



2011-2012 FoodCORE Study

- All of the non-O157 STEC and 6% of the O157 STEC (negative by culture at the clinical system site) would have been unreported had the three clinical system sites not been screening for Stx
- Of the 75 cases (out of 83) for which epidemiological data is available, there were 23 hospitalizations (18 O157, 5 non-O157), no deaths or HUS cases and the median age was 19 (age range from 0-89 years)



2011-2012 FoodCORE Study

- Positivity rates for Stx among all three clinical system site stool specimens averaged near 1% over the study period
- There were a total of 6 O157 STEC isolates (7.2%) during the study period that were included in national PulseNet clusters; no non-O157 STEC were included in national clusters
- Both the microplate EIA and RCA Stx diagnostic assays performed well; of all positive GN broths, WSLH isolated STEC from 92%



It Takes Teamwork...



Effective STEC disease diagnosis, surveillance and prevention takes a concerted effort by clinical health systems, public health laboratories, public health epidemiologists and env. health officials



How do We Partner to Prevent STEC and Other Diseases?



Gemplers.com



Extremehaltradio.com



Role of Clinical Health Systems

- Disease diagnosis and patient management is the primary focus; Clinical laboratories will generally be the first to see infectious disease cases
- Responsibility to notify local health officials, within the patient jurisdiction, of reportable disease cases as they detect them
- Prevention of spread of further communicable disease from index case(s)
- Responsible use of antibiotics; reduce development of antimicrobial resistance




Role of WSLH

- Laboratory service for the Wisconsin Division of Public Health (WDPH)
- Laboratory response to clusters of disease or pathogens of public health significance; emergency response
- Surveillance for public health pathogens
- Antimicrobial resistance monitoring
- Public health education and safety
- Research and specialized testing



Role of Local Health Officials

- Receive reportable disease information from clinical health systems or the public within their jurisdiction
- Investigate disease cases or clusters
- Disseminate disease information to WDPH





Role of WDPH

- Receive disease reports from local health, clinical health and environmental health officials
- SOS (Surveillance and Outbreak Support) Team will interview and enter epi data from cases in real time into a database; **Epi's** often have data in hand when they receive lab data from WSLH



Role of WDPH

- Receive lab data (PFGE subtyping, AST, Stx) from WSLH
- Work with other state and CDC **epi's** as needed to respond to regional or national clusters of illness
- Lead and coordinate cluster investigations
- Public Health education



Role of Environmental Health Sanitarians

- Work closely with Dept of Agriculture, Trade and Consumer Protection officials
- Conduct environmental health inspections and related activities for locations such as:
 - Restaurants
 - Hotels
 - Swimming pools and beaches
- Enforce public health laws and sanitary codes
- Investigate outbreaks, injuries, exposures, etc





2006 Multi-State Spinach E. coli O157: H7 Outbreak





O157:H7 Spinach Outbreak- 2006

- Cluster of *E. coli* O157:H7 detected by PFGE subtyping in WI
- Reports to WDPH of multiple cases of HUS in the Milwaukee area
- Total of 204 cases of *E. coli* O157:H7 attributed to the spinach exposure; 49 of which were WI residents
- There were 104 patients hospitalized (51%), 31 cases of HUS (16%) and 3 deaths (1 WI)



O157:H7 Spinach Outbreak- 2006

- Epi investigation traced source back to spinach field in CA
- Environmental sampling in the area led to the *E. coli* O157:H7 outbreak strain being detected from cattle on an adjacent farm, wild pig feces in the field and water in an irrigation channel in the field (confirmed by PFGE and MLVA subtyping)



O157:H7 Spinach Outbreak- 2006

- Interestingly, one WI case was also determined to have a dual STEC infection; the outbreak O157:H7 and a non-O157 STEC
- NM state laboratory isolated the same non-O157 STEC from a bag of the implicated spinach
- How many other non-O157 STEC infections were there from the implicated spinach exposure?



O104:H4 STEC Outbreak


- May 2011 cluster of HUS cases detected in Germany
- No equivalent of PulseNet in Germany; Surveillance based on HUS case reporting
- Almost 4000 cases, 1000 HUS cases and 50 deaths attributed to the outbreak in the end
- Eventually linked to contaminated sprouts germinated from fenugreek seeds that originated in Egypt





O104:H4 STEC Outbreak

- O104:H4 novel strain; only seen in 2006 Japan and 2009 Rep. of Georgia human illness cases
- High interest in enhanced virulence ; genomic sequencing revealed the origin of this strain was likely an O157:H7 strain exchanging genetic material with an EAEC O104:H4 in the gut of a human





O104:H4 STEC Outbreak

Emerging Pathogens: Is E. Coli O104:H4 the Next Strain to Watch? | Food Safety News - Windows Internet Explorer

FSN <http://www.foodsafetynews.com/2013/09/e-coli-o104h4-the-next-strain-to-watch/>

File Edit View Favorites Tools Help

Favorites <https://climicro.asm.org/im...> [ASM Home](#) [Free Hotmail](#) [List of Bacterial Names](#) [MICRO LINKS](#) [Suggested Sites](#) [Web Slice Gallery](#)

FSN Emerging Pathogens: Is E. Coli O104:H4 the Next Str...

Food Safety News

Breaking news for everyone's consumption

Home Foodborne Illness Outbreaks Food Recalls Food Politics Events Subscribe About Us Directory

Emerging Pathogens: Is E. Coli O104:H4 the Next Strain to Watch?

BY JAMES ANDREWS | SEPTEMBER 9, 2013

In May 2011, a virtually unknown strain of E. coli, known as O104:H4, made worldwide headlines when an outbreak in Germany sickened approximately 4,000 people and killed 50, including one American. This event, linked to fresh sprouts, quickly became the deadliest foodborne illness outbreak in history.



In the days following the first reports of illness, microbiological research laboratories around the globe began pooling resources to coordinate the world's first "open source" analysis of a microbial genome. In turn, this spurred an unprecedented level of focused study by international collaborators that is still going on two years later.

Before the German outbreak, the only reported illness associated with O104:H4 was in South Korea and involved a solitary case of hemolytic uremic syndrome, or HUS, a potentially fatal kidney disease associated with severe E. coli infections.

Little to no research had focused on the rare strain leading up to its record-setting outbreak. But, as soon as it hit, O104:H4 rose in notoriety to a status reserved for E. coli O157:H7, the strain that has caused numerous deadly outbreaks in the past two decades and made E. coli a household name.

Thanks to recent technological advancements in DNA sequencing, researchers around the world were able to map the genome of O104:H4 within days – a feat that would have taken months if the outbreak had happened a decade earlier.

By working together to analyze the genome, researchers could more quickly determine why O104:H4 might be so particularly deadly.

Contact Us

- Subscribe for Free via Email or RSS
- Like Food Safety News on Facebook
- Follow Food Safety News on Twitter
- Connect with Food Safety News on LinkedIn



MOST READ ON FOOD SAFETY NEWS

- Fermenting Veggies at Home: Follow Food Safety ABCs
- Meat Recalls – Slaughter Plant Shutdowns = Supplier for the National School Lunch Program?
- FDA Suspends Registration of Cheese Manufacturer Over Health Risk

<http://www.foodsafetynews.com/files/2013/08/E.-coli.jpg>

Internet 100%



O45 STEC Associated with a WI Meat Processor- 2010-12

- Dec 2010, WSLH identifies matching/ closely matching PFGE patterns for four O45 STEC isolates (3 WI residents and 1 MI resident)
- Epi investigation leads to 3 more probable cases (1WI and 2 MI) and an interesting foodborne exposure **scenario...**



O45 STEC Associated with a WI Meat Processor- 2010-12

- Case patient food exposure histories lead to consumption of bear meat sticks as illness source
- Meat sticks were prepared with beef and bear meat
- Venison contamination found in beef sausage
- True source (beef, bear, venison)?





O45 STEC Associated with a WI Meat Processor- 2010-12

- WDPH **Epi's** thought this investigation was in **the books but...**
- Nov 2011, a new O45 STEC isolate with the same PFGE pattern is identified at WSLH
- Epi investigation finds that patient had venison processed at the same meat processor implicated in the 2010 outbreak



O45 STEC Associated with a WI Meat Processor- 2010-12

- Fast forward to May 2012: Dane county resident O45 STEC isolate determined to match the outbreak strain by PFGE
- Epi investigation by WDPH and local HD reveals (you guessed it) this patient also had venison processed at the same meat processor
- Health officials determined to find source of these infections



O45 STEC Associated with a WI Meat Processor- 2010-12

- In addition to environmental sampling, all employees were screened for Stx
- One employee Stx positive in June 2012
- Interestingly though, the culture yields an O146:H21 STEC, not O45 STEC as was suspected
- To date, no further O45 STEC cases linked to **the meat processor...but hunting season begins again next Fall!**



WI Tiger Meat Outbreaks- 2012 and 2013





WI Tiger Meat Outbreaks- 2012 and 2013

- **It's** a Holiday Tradition!
- Jan 2013, two cases of *E. coli* O157:H7 with matching PFGE patterns reported to WDPH; two more would be linked later
- Epi investigation links the cases to raw ground beef purchased at the same meat market
- 17 cases would be identified with raw beef exposure (14 consumed/ 3 cross contam.)



WI Tiger Meat Outbreaks- 2012 and 2013

- Dec 2013...It's still a Holiday tradition!
- 3 *E. coli* O157:H7 STEC isolates identified that have matching PFGE patterns
- Epi investigation determines 2/3 had consumed raw ground beef as Tiger Meat/cannibal sandwiches
- Definitive source of beef not identified after a thorough investigation by PH officials



Culture Independent Diagnostic Tests- Impact on Patient Mgmt

- In many cases, will detect pathogens more quickly than traditional detection methods
- Multiplex assays will pick up multiple **pathogens in a single specimen...clinical significance of one, both, all?**
- Loss of isolate for antimicrobial susceptibility testing (if needed)



Culture Independent Diagnostic

Tests- Impact on Public Health

- Potential loss of isolates if clinical health system discontinues enteric bacterial culture (current basis for surveillance)
 - Loss of isolate for serotyping and subtyping
 - Loss of isolate for antimicrobial resistance testing
- Greater resources necessary to perform enteric culture on specimens received from clinical health systems



Specimen Submissions

- As with other enteric specimens, STEC specimens may be submitted to WSLH via overnight courier as part of the **W**isconsin **E**nteric **P**athogen **S**urveillance (WEPS) Program
- Contact Dunham Express courier service: 800-236-7127 (account 7271)
- For technical questions, call WSLH: 800-862-1013



CDD Requisition Form A

Bacteriology:		Bacteriology:		Parasitology:	
MP00470	Bacterial ID, Non-Enteric Public Health Panel (WEIP); Suspect Organism: _____	MP00593	Toxic Shock Syndrome Toxins	MP00800	Arthropod Identification
		BT Agent (Potential), please call 800-862-1013		MP00802	Cryptosporidium/Giardia DFA
MP00628	Bacterial Typing (PFGE) Organism _____	WSLH assigned	<i>Suspect Agent (please circle)</i> • Burkholderia mallei/pseudomallei • Bacillus anthracis • Francisella • Brucella • Yersinia pestis	MP00840	Ova & Parasites, Intestinal
MP00623	Bordetella Culture			MP00880	Parasites Blood Smear Suspect Parasite _____
MP00311	Bordetella PCR			MP00881	Parasites Tissue Smear Suspect Parasite _____
	Botulism Testing (Call 800-862-1013)			Invasive Bacteriology Surveillance (IBLS):	
SC00111	Chlamydia/GC NAAT	MP00666	Group A Beta Streptococcus	MP00860	Worm Identification
SC00118	Chlamydia trachomatis NAAT	MP00666	Group B Beta Streptococcus	Virology:	
SC00112	Neisseria gonorrhoeae NAAT	MP00651	Haemophilus influenzae	VR01703	Enterovirus PCR (CSF)
VR01502	Chlamydia trachomatis Culture	MP00628	Listeria monocytogenes	VR01704	Herpes Simplex Virus PCR (Genital/Dermal)
MP00681	CRE (KPC/NDM-1) PCR Organism _____ Attach Susceptibility Results	MP00561	Neisseria meningitidis	VR01705	Herpes Simplex Virus PCR (CSF)
		MP00465	Streptococcus pneumoniae	VR01713	Measles Virus PCR
MP00380	Diphtheria Culture	Mycobacteriology:		VR01714	Mumps Virus PCR
MP00460	Enteric Pathogen Isolate Identification (WEPS) Suspect Organism _____	MM00250	Mycobacteria (AFB) Smear and Culture	VR01717	Norovirus PCR
		MM00253	Mycobacteria Isolate Identification	VR01725	Rubella Virus PCR
MP00610	Haemophilus ducreyi Culture	MM00202	Mycobacterium avium Complex (MAC) Susceptibility	VR01727	Varicella Zoster Virus PCR
MP00420	Legionella Clinical Culture			VR01725	Rubella Virus PCR
MP00421	Legionella PCR	MM00204	Mycobacterium tuberculosis Susceptibility- 1st Line Drugs	VR01727	Varicella Zoster Virus PCR
MP00549	Shiga Toxin EIA			Other Tests (Specify):	
MP00536	Shiga Toxin PCR Screen	MM00207	Mycobacteria Rapid Grower Susceptibility		
MP00684	S. aureus for VISA/VRSA Confirmation	MM00256	Mycobacterium tuberculosis PCR Decontaminated? Yes No Smear Result _____		
MP00660	Stool Culture, Routine Suspect Organism _____				

**WHITE-RETURN TO WSLH
YELLOW-KEEP FOR YOUR RECORDS**



Summary

- STEC disease is a significant cause of morbidity and mortality in WI and nationally; there are significant costs, both human and monetary
- here are multiple diagnostic testing options available for Stx detection with many more in development
- WI clinical health systems have been testing for Stx for many years; currently there is effective statewide Stx diagnostic testing which is critical for STEC diagnosis, surveillance and prevention



Summary

- **CIDT's have proven beneficial to STEC and other disease diagnoses; however they have the potential for adverse impact on current isolate-based public health surveillance systems**
- Effective STEC disease detection, surveillance and prevention requires a strong partnership among clinical and public health agencies and officials; we believe such a partnership exists today in WI



Acknowledgements

- Rachel Klos, Traci DeSalvo and Justin Kohl-WDPH state foodborne disease epidemiologists
- Three FoodCORE STEC enhancement initiative sites:
 - Marshfield Clinic
 - **St. Mary's Hospital**- Madison
 - Fort Healthcare
- Colleagues in the WSLH Bacteriology and PFGE laboratories
- Clinical health systems and laboratorians in WI



Contact Information

Mike Rauch

Advanced Microbiologist

michael.rauch@slh.wisc.edu

Tim Monson

Microbiologist Supervisor

timothy.monson@slh.wisc.edu

WSLH CDD Customer Service (800-862-1013)



Questions?

